Loading...
Header Logo
Institute for Clinical and Translational Research

Profiles



Video Tutorials
Keywords
Last Name
Institution

SRDAN VERSTOVSEK

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019 Aug 13; 3(15):2264-2271. PMID: 31350306.
      View in: PubMed
    2. Economides MP, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2019 Aug 01. PMID: 31372878.
      View in: PubMed
    3. Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019 Aug; 14(4):310-327. PMID: 31228096.
      View in: PubMed
    4. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2019 Jul 11. PMID: 31296578.
      View in: PubMed
    5. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 May 24; 1-9. PMID: 31125272.
      View in: PubMed
    6. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019 Jul; 98(7):1611-1616. PMID: 31093708.
      View in: PubMed
    7. Masarova L, Verstovsek S. Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs. 2019 Jun; 24(2):93-105. PMID: 31050912.
      View in: PubMed
    8. Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol. 2019 May; 17(5):299-307. PMID: 31188809.
      View in: PubMed
    9. Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Apr 23. PMID: 31013548.
      View in: PubMed
    10. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26; 3(6):851-861. PMID: 30885996.
      View in: PubMed
    11. Pettit K, Verstovsek S, Talpaz M. SOHO State of the Art Updates and Next Questions: Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2019 Apr; 19(4):191-199. PMID: 30987952.
      View in: PubMed
    12. Boddu P, Carter BZ, Verstovsek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. 2019 Apr; 185(2):219-231. PMID: 30836448.
      View in: PubMed
    13. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 Jun 01; 125(11):1855-1866. PMID: 30811597.
      View in: PubMed
    14. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 May 23; 133(21):2348-2351. PMID: 30796023.
      View in: PubMed
    15. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood. 2019 May 23; 133(21):2320-2324. PMID: 30745304.
      View in: PubMed
    16. Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 Jan 24; 20(1):5. PMID: 30675650.
      View in: PubMed
    17. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 Jul; 60(7):1767-1774. PMID: 30632841.
      View in: PubMed
    18. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear ß-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 Jun; 33(6):1373-1386. PMID: 30575820.
      View in: PubMed
    19. Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta Haematol. 2019; 141(1):23-27. PMID: 30463063.
      View in: PubMed
    20. Hu Z, Ramos CEB, Medeiros LJ, Zhao C, Yin CC, Li S, Hu S, Wang W, Thakral B, Xu J, Verstovsek S, Lin P. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. Hum Pathol. 2019 Mar; 85:290-298. PMID: 30447300.
      View in: PubMed
    21. Masarova L, Verstovsek S. Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere. J Clin Oncol. 2018 Oct 22; JCO2018793497. PMID: 30346901.
      View in: PubMed
    22. Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA. A multimodality work-up of patients with Hypereosinophilia. Am J Hematol. 2018 11; 93(11):1337-1346. PMID: 30105844.
      View in: PubMed
    23. Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. J Hematol Oncol. 2018 Sep 24; 11(1):122. PMID: 30249277.
      View in: PubMed
    24. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103. PMID: 30242087.
      View in: PubMed
    25. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85. PMID: 30245189.
      View in: PubMed
    26. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematol Oncol. 2018 Oct; 36(4):701-708. PMID: 30105794.
      View in: PubMed
    27. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431.
      View in: PubMed
    28. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541.
      View in: PubMed
    29. Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematol Oncol. 2018 Dec; 36(5):740-748. PMID: 30074634.
      View in: PubMed
    30. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol. 2019 Apr; 185(2):382-386. PMID: 30074241.
      View in: PubMed
    31. Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P, Castells MC. Patient Perceptions in Mast Cell Disorders. Immunol Allergy Clin North Am. 2018 08; 38(3):505-525. PMID: 30007467.
      View in: PubMed
    32. Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann Oncol. 2018 Aug 01; 29(8):1880-1882. PMID: 29767670.
      View in: PubMed
    33. Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma. 2019 Feb; 60(2):507-510. PMID: 29966471.
      View in: PubMed
    34. Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol. 2018 Nov; 97(11):2071-2080. PMID: 29951914.
      View in: PubMed
    35. Falchi L, Verstovsek S. Kit Mutations: New Insights and Diagnostic Value. Immunol Allergy Clin North Am. 2018 08; 38(3):411-428. PMID: 30007460.
      View in: PubMed
    36. Bose P, Verstovsek S. Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172. PMID: 29796726.
      View in: PubMed
    37. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984.
      View in: PubMed
    38. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018 May 01; 4(5):652-659. PMID: 29522138.
      View in: PubMed
    39. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447. PMID: 29567676.
      View in: PubMed
    40. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191. PMID: 29557496.
      View in: PubMed
    41. Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018 Mar 15; 11(1):42. PMID: 29544547.
      View in: PubMed
    42. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146. PMID: 29550383.
      View in: PubMed
    43. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 05; 32(5):1057-1069. PMID: 29515238.
      View in: PubMed
    44. Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018 Apr; 97(4):617-627. PMID: 29396713.
      View in: PubMed
    45. Verstovsek S. Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2018 Feb; 16 Suppl 4(2):20-23. PMID: 29742090.
      View in: PubMed
    46. Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263. PMID: 29226426.
      View in: PubMed
    47. Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12. PMID: 29277359.
      View in: PubMed
    48. Hidalgo López JE, Carballo-Zarate A, Verstovsek S, Wang SA, Hu S, Li S, Xu J, Zuo W, Tang Z, Yin CC, Medeiros LJ, Bueso-Ramos CE, Tang G. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018 Mar; 97(3):425-434. PMID: 29285580.
      View in: PubMed
    49. Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb; 5(2):e73-e81. PMID: 29275119.
      View in: PubMed
    50. Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol. 2018 12; 183(5):831-835. PMID: 29265180.
      View in: PubMed
    51. Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep. 2018 01; 6(1):155-161. PMID: 29375856.
      View in: PubMed
    52. Stein BL, Verstovsek S. Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right? Curr Hematol Malig Rep. 2017 12; 12(6):507-509. PMID: 29032412.
      View in: PubMed
    53. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. PMID: 29134664.
      View in: PubMed
    54. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018 Jan; 97(1):109-121. PMID: 29143068.
      View in: PubMed
    55. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30. PMID: 29152412.
      View in: PubMed
    56. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90. PMID: 29027261.
      View in: PubMed
    57. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676. PMID: 29119847.
      View in: PubMed
    58. Bose P, Verstovsek S. Ruxolitinib for essential thrombocythemia? Oncoscience. 2017 Nov; 4(11-12):148-149. PMID: 29344542.
      View in: PubMed
    59. Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE, Sanchez-Petitto G, Verstovsek S. JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leuk Res. 2017 12; 63:53-55. PMID: 29101828.
      View in: PubMed
    60. Verstovsek S, Fiskus W, Manshouri T, Bhalla KN. Targeting cistrome and dysregulated transcriptome of post-MPN sAML. Oncotarget. 2017 Nov 07; 8(55):93301-93302. PMID: 29212143.
      View in: PubMed
    61. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430.
      View in: PubMed
    62. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017 10; 15(10):1193-1207. PMID: 28982745.
      View in: PubMed
    63. Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017 09 29; 10(1):156. PMID: 28962635.
      View in: PubMed
    64. Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT. A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk Res. 2017 10; 61:89-95. PMID: 28934680.
      View in: PubMed
    65. Masarova L, Verstovsek S, Kantarjian H, Daver N. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol. 2017 10; 10(10):903-914. PMID: 28799436.
      View in: PubMed
    66. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 10 12; 130(15):1768-1771. PMID: 28827411.
      View in: PubMed
    67. Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017 Oct; 96(10):1595-1604. PMID: 28808761.
      View in: PubMed
    68. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. PMID: 28743165.
      View in: PubMed
    69. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
      View in: PubMed
    70. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131. PMID: 28674026.
      View in: PubMed
    71. Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S43-S52. PMID: 28760302.
      View in: PubMed
    72. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116. PMID: 28601551.
      View in: PubMed
    73. Hidalgo-López JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CE. Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw. 2017 06; 15(6):790-796. PMID: 28596259.
      View in: PubMed
    74. Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res. 2017 08; 59:105-109. PMID: 28599188.
      View in: PubMed
    75. Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017 09; 60:11-17. PMID: 28622623.
      View in: PubMed
    76. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866. PMID: 29296729.
      View in: PubMed
    77. Falchi L, Kantarjian HM, Verstovsek S. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017 09; 31(9):1845-1854. PMID: 28529308.
      View in: PubMed
    78. Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol. 2018 07; 182(2):279-284. PMID: 29984424.
      View in: PubMed
    79. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125. PMID: 28500170.
      View in: PubMed
    80. Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk. 2017 08; 17(8):479-487. PMID: 28606598.
      View in: PubMed
    81. Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos CE, Arber DA, Verstovsek S, Orazi A. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360. PMID: 28495918.
      View in: PubMed
    82. Bose P, Abou Zahr A, Verstovsek S. Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017 Jun; 26(6):723-734. PMID: 28441920.
      View in: PubMed
    83. Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017 09; 102(9):1511-1518. PMID: 28473622.
      View in: PubMed
    84. Khan M, Yin CC, Yates A, Newberry KJ, Verstovsek S. A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia. J Pediatr Hematol Oncol. 2017 05; 39(4):e196-e198. PMID: 27403772.
      View in: PubMed
    85. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017 Jul; 96(7):1113-1120. PMID: 28456851.
      View in: PubMed
    86. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472.
      View in: PubMed
    87. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922.
      View in: PubMed
    88. Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov Z. A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. Blood Res. 2017 Mar; 52(1):71-73. PMID: 28401108.
      View in: PubMed
    89. Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol. 2017 07; 30(7):940-951. PMID: 28338652.
      View in: PubMed
    90. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659. PMID: 28338082.
      View in: PubMed
    91. Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res. 2017 07; 58:14-22. PMID: 28380402.
      View in: PubMed
    92. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175. PMID: 28291640.
      View in: PubMed
    93. Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88. PMID: 28324773.
      View in: PubMed
    94. Assi R, Verstovsek S, Daver N. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol. 2017 03; 24(2):115-124. PMID: 28072602.
      View in: PubMed
    95. Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma. 2017 10; 58(10):2508-2510. PMID: 28264600.
      View in: PubMed
    96. Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738. PMID: 28247057.
      View in: PubMed
    97. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 02 22; 10(1):55. PMID: 28228106.
      View in: PubMed
    98. Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Br J Haematol. 2017 Mar; 176(6):939-949. PMID: 28220932.
      View in: PubMed
    99. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961. PMID: 28042144.
      View in: PubMed
    100. Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017 05; 56:52-59. PMID: 28193568.
      View in: PubMed
    101. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238.
      View in: PubMed
    102. Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 02 11; 389(10069):612-620. PMID: 28069279.
      View in: PubMed
    103. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274.
      View in: PubMed
    104. Falchi L, Bose P, Newberry KJ, Verstovsek S. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol. 2017 Feb; 176(3):352-364. PMID: 27984634.
      View in: PubMed
    105. Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137. PMID: 27931243.
      View in: PubMed
    106. Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 12; 14(12):1572-1611. PMID: 27956542.
      View in: PubMed
    107. Bose P, Verstovsek S. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624. PMID: 27956543.
      View in: PubMed
    108. Abaza Y, Yin CC, Bueso-Ramos CE, Wang SA, Verstovsek S. Primary autoimmune myelofibrosis: a case report and review of the literature. Int J Hematol. 2017 Apr; 105(4):536-539. PMID: 27830539.
      View in: PubMed
    109. Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 Jan; 176(1):76-85. PMID: 27858987.
      View in: PubMed
    110. Bose P, Verstovsek S. Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016 Dec; 17(18):2375-2389. PMID: 27774820.
      View in: PubMed
    111. Bose P, Verstovsek S. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016 Dec; 25(12):1393-1403. PMID: 27756180.
      View in: PubMed
    112. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324. PMID: 27795561.
      View in: PubMed
    113. Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 02; 102(2):327-335. PMID: 27789678.
      View in: PubMed
    114. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. PMID: 27763690.
      View in: PubMed
    115. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637. PMID: 27741352.
      View in: PubMed
    116. Verstovsek S. Highlights in polycythemia vera from the 2016 EHA congress. Clin Adv Hematol Oncol. 2016 Oct; 14(10):810-813. PMID: 27930632.
      View in: PubMed
    117. Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016 10; 101(10):1133-1143. PMID: 27694501.
      View in: PubMed
    118. Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov Z. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84. PMID: 27686378.
      View in: PubMed
    119. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687. PMID: 27677740.
      View in: PubMed
    120. Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017 01; 102(1):94-102. PMID: 27634203.
      View in: PubMed
    121. Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016 12; 101(12):e482-e484. PMID: 27587385.
      View in: PubMed
    122. Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol. 2016 Oct; 104(4):420-9. PMID: 27567907.
      View in: PubMed
    123. Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol. 2016; 8:11-9. PMID: 27574472.
      View in: PubMed
    124. Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871. PMID: 27494751.
      View in: PubMed
    125. Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402. PMID: 27479177.
      View in: PubMed
    126. Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13. PMID: 27521306.
      View in: PubMed
    127. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40. PMID: 27481130.
      View in: PubMed
    128. Nazha A, Khoury JD, Verstovsek S, Daver N. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? Crit Rev Oncol Hematol. 2016 Sep; 105:112-7. PMID: 27401783.
      View in: PubMed
    129. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res. 2016 09; 48:1-5. PMID: 27416326.
      View in: PubMed
    130. Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 2016 08 11; 128(6):877-80. PMID: 27325105.
      View in: PubMed
    131. Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016 06; 101(6):660-71. PMID: 27252511.
      View in: PubMed
    132. Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 08; 29(8):854-64. PMID: 27174585.
      View in: PubMed
    133. Vaddi K, Verstovsek S, Kiladjian JJ. Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Blood Lymphat Cancer. 2016; 6:7-19. PMID: 31360077.
      View in: PubMed
    134. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356. PMID: 27131865.
      View in: PubMed
    135. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 07; 101(7):821-9. PMID: 27102499.
      View in: PubMed
    136. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol. 2016 05 15; 196(10):4400-9. PMID: 27076684.
      View in: PubMed
    137. Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol. 2016 06; 77(6):1125-42. PMID: 27017614.
      View in: PubMed
    138. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27. PMID: 27124925.
      View in: PubMed
    139. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26. PMID: 26846160.
      View in: PubMed
    140. Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):213-222.e2. PMID: 26838606.
      View in: PubMed
    141. Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016 Aug; 97(2):192-200. PMID: 26608702.
      View in: PubMed
    142. Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016 Apr 15; 122(8):1160-8. PMID: 26716387.
      View in: PubMed
    143. Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016 Mar 01; 122(5):681-92. PMID: 26717494.
      View in: PubMed
    144. Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1969-73. PMID: 26700872.
      View in: PubMed
    145. Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia. 2016 06; 30(6):1413-5. PMID: 26526986.
      View in: PubMed
    146. Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55. PMID: 26486739.
      View in: PubMed
    147. Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40. PMID: 26493563.
      View in: PubMed
    148. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma. 2016 May; 57(5):1054-9. PMID: 26402369.
      View in: PubMed
    149. Livun A, Newberry KJ, Manshouri T, Kusec R, Verstovsek S. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer Res. 2015 Oct; 35(10):5219-23. PMID: 26408680.
      View in: PubMed
    150. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9. PMID: 25904378.
      View in: PubMed
    151. Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2015; 11(20):2819-30. PMID: 26367195.
      View in: PubMed
    152. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73. PMID: 26365212.
      View in: PubMed
    153. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885.
      View in: PubMed
    154. Falchi L, Verstovsek S. Eosinophilia in Hematologic Disorders. Immunol Allergy Clin North Am. 2015 Aug; 35(3):439-52. PMID: 26209894.
      View in: PubMed
    155. Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol. 2015 Aug 01; 16:121. PMID: 26232031.
      View in: PubMed
    156. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015 Sep 24; 126(13):1551-4. PMID: 26228487.
      View in: PubMed
    157. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7. PMID: 26124496.
      View in: PubMed
    158. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63. PMID: 26088933.
      View in: PubMed
    159. Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol. 2015 Dec; 37(6):e150-2. PMID: 26086872.
      View in: PubMed
    160. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6. PMID: 26183878.
      View in: PubMed
    161. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep; 100(9):1139-45. PMID: 26069290.
      View in: PubMed
    162. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62. PMID: 26141213.
      View in: PubMed
    163. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S27-33. PMID: 26297275.
      View in: PubMed
    164. Verstovsek S. New therapies for polycythemia vera. Clin Adv Hematol Oncol. 2015 Jun; 13(6):356-8. PMID: 26352890.
      View in: PubMed
    165. Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015 May 21; 125(21):3352-3. PMID: 25999444.
      View in: PubMed
    166. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3. PMID: 25999449.
      View in: PubMed
    167. Stein BL, Cervantes F, Giles F, Harrison CN, Verstovsek S. Novel therapies for myelofibrosis. Leuk Lymphoma. 2015; 56(10):2768-78. PMID: 25860240.
      View in: PubMed
    168. Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015 Aug; 8(4):391-401. PMID: 25980454.
      View in: PubMed
    169. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. PMID: 26012362.
      View in: PubMed
    170. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2. PMID: 25808231.
      View in: PubMed
    171. Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res. 2015 Jul; 39(7):684-8. PMID: 25922307.
      View in: PubMed
    172. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr; 13(4):424-34. PMID: 25870379.
      View in: PubMed
    173. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28. PMID: 26687797.
      View in: PubMed
    174. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2. PMID: 25795639.
      View in: PubMed
    175. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7. PMID: 25641433.
      View in: PubMed
    176. Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015 Apr; 39(4):419-23. PMID: 25687833.
      View in: PubMed
    177. Van Roosbroeck K, Verstovsek S, Calin GA. Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells? Leuk Lymphoma. 2015 Feb; 56(2):281-2. PMID: 25093380.
      View in: PubMed
    178. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29; 372(5):426-35. PMID: 25629741.
      View in: PubMed
    179. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Apr; 100(4):479-88. PMID: 25616577.
      View in: PubMed
    180. Arana Yi C, Tam CS, Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 2015; 11(5):719-33. PMID: 25757677.
      View in: PubMed
    181. Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015 Apr; 15(4):214-221.e1. PMID: 25682576.
      View in: PubMed
    182. Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015 Jul; 29(4):215-21. PMID: 25577686.
      View in: PubMed
    183. Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014 Dec 16; 111(50):E5401-10. PMID: 25516983.
      View in: PubMed
    184. Yacoub A, Odenike O, Verstovsek S. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014 Dec; 9(4):350-9. PMID: 25145552.
      View in: PubMed
    185. Verstovsek S, Hoffman R, Mascarenhas J, Soria JC, Bahleda R, McCoon P, Tang W, Cortes J, Kantarjian H, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2015 Feb; 39(2):157-63. PMID: 25530567.
      View in: PubMed
    186. Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):253-61. PMID: 25515354.
      View in: PubMed
    187. Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. 2015 Feb; 8(1):101-13. PMID: 25353086.
      View in: PubMed
    188. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53. PMID: 25312977.
      View in: PubMed
    189. Passamonti F, Vannucchi AM, Cervantes F, Harrison C, Morra E, Kantarjian H, Verstovsek S. Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia. 2015 Mar; 29(3):739-40. PMID: 25249013.
      View in: PubMed
    190. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6. PMID: 25441108.
      View in: PubMed
    191. Jabbar KJ, Medeiros LJ, Wang SA, Miranda RN, Johnson MR, Verstovsek S, Jorgensen JL. Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow. Arch Pathol Lab Med. 2014 Sep; 138(9):1210-4. PMID: 25171703.
      View in: PubMed
    192. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6. PMID: 25217891.
      View in: PubMed
    193. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2015 Jan; 29(1):20-6. PMID: 25151955.
      View in: PubMed
    194. Verstovsek S. Preface. Best Pract Res Clin Haematol. 2014 Jun; 27(2):81-2. PMID: 25189719.
      View in: PubMed
    195. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4. PMID: 25107338.
      View in: PubMed
    196. Daver N, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma. 2015 Feb; 56(2):279-80. PMID: 24913500.
      View in: PubMed
    197. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9. PMID: 25047979.
      View in: PubMed
    198. Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, Zollman A, Kamoka MM, Mu J, Chen DZ, Srour EF, Chitteti BR, HogenEsch H, Tu X, Bellido TM, Boswell HS, Manshouri T, Verstovsek S, Yoder MC, Kapur R, Cardoso AA, Carlesso N. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-?B-dependent manner. Cell Stem Cell. 2014 Jul 03; 15(1):51-65. PMID: 24996169.
      View in: PubMed
    199. Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S. Comorbidities predict worse prognosis in patients with primary myelofibrosis. Cancer. 2014 Oct 01; 120(19):2996-3002. PMID: 24917509.
      View in: PubMed
    200. Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol. 2014; 4:130. PMID: 24918086.
      View in: PubMed
    201. Santos FP, Verstovsek S. Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharmacother. 2014 Jul; 15(10):1465-73. PMID: 24856675.
      View in: PubMed
    202. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014 Oct; 28(10):2090-2. PMID: 24854988.
      View in: PubMed
    203. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152.
      View in: PubMed
    204. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hägglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014 Sep; 25(9):1691-700. PMID: 24675021.
      View in: PubMed
    205. Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1274-81. PMID: 24680977.
      View in: PubMed
    206. Verstovsek S. Changing myelofibrosis's natural course at last. Blood. 2014 Mar 20; 123(12):1776-7. PMID: 24652960.
      View in: PubMed
    207. Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014 Dec; 55(12):2685-90. PMID: 24524340.
      View in: PubMed
    208. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 01; 36(4):560-6. PMID: 24636526.
      View in: PubMed
    209. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51. PMID: 24627528.
      View in: PubMed
    210. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15; 120(4):513-20. PMID: 24258498.
      View in: PubMed
    211. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014; 7:89-101. PMID: 24501543.
      View in: PubMed
    212. Nazha A, Jorgensen JL, Verstovsek S. Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. Leuk Lymphoma. 2014 Sep; 55(9):2215-6. PMID: 24359246.
      View in: PubMed
    213. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61. PMID: 24492324.
      View in: PubMed
    214. Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013; 7:13-21. PMID: 24368888.
      View in: PubMed
    215. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145.
      View in: PubMed
    216. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214.
      View in: PubMed
    217. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728.
      View in: PubMed
    218. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30. PMID: 24355079.
      View in: PubMed
    219. Arana Yi C, Jeyakumar G, Medina P, Cortes J, Pierce S, Bueso-Ramos C, Kantarjian H, Verstovsek S. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leuk Res. 2014 Jan; 38(1):91-4. PMID: 24284333.
      View in: PubMed
    220. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood. 2013 Nov 07; 122(19):3387-8. PMID: 24203930.
      View in: PubMed
    221. Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ, Wang SA. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014 May; 27(5):681-9. PMID: 24186132.
      View in: PubMed
    222. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81. PMID: 24283202.
      View in: PubMed
    223. Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol. 2013 Oct; 6(5):511-23. PMID: 24083419.
      View in: PubMed
    224. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6. PMID: 24068492.
      View in: PubMed
    225. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9. PMID: 24060289.
      View in: PubMed
    226. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec; 98(12):1865-71. PMID: 24038026.
      View in: PubMed
    227. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852.
      View in: PubMed
    228. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6. PMID: 23993426.
      View in: PubMed
    229. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7. PMID: 23993427.
      View in: PubMed
    230. Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leuk Lymphoma. 2014 Jan; 55(1):5-6. PMID: 23829281.
      View in: PubMed
    231. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014 Feb; 99(2):292-8. PMID: 23911705.
      View in: PubMed
    232. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4. PMID: 23890523.
      View in: PubMed
    233. Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol. 2013 Oct; 91(4):378-9. PMID: 23772772.
      View in: PubMed
    234. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22; 122(8):1395-8. PMID: 23838352.
      View in: PubMed
    235. Verstovsek S. Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival. Oncology (Williston Park). 2013 Jul; 27(7):717-8. PMID: 23977769.
      View in: PubMed
    236. Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 2013 Sep; 98(9):1421-3. PMID: 23812932.
      View in: PubMed
    237. Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):629-33. PMID: 23800601.
      View in: PubMed
    238. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901. PMID: 23782935.
      View in: PubMed
    239. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84. PMID: 23770156.
      View in: PubMed
    240. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. PMID: 23701251.
      View in: PubMed
    241. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013 Aug; 37(8):911-6. PMID: 23684482.
      View in: PubMed
    242. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7. PMID: 23573823.
      View in: PubMed
    243. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013 Oct; 92(10):1335-43. PMID: 23660629.
      View in: PubMed
    244. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74. PMID: 23620574.
      View in: PubMed
    245. Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma. 2013 Dec; 54(12):2667-70. PMID: 23488603.
      View in: PubMed
    246. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 06; 121(23):4778-81. PMID: 23591792.
      View in: PubMed
    247. Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers. 2013 May; 17(5):429-37. PMID: 23537216.
      View in: PubMed
    248. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013 May; 161(4):508-16. PMID: 23480528.
      View in: PubMed
    249. Santos FP, Verstovsek S. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis? Curr Opin Hematol. 2013 Mar; 20(2):123-9. PMID: 23385614.
      View in: PubMed
    250. Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, Jones DM, Bueso-Ramos C, Verstovsek S, Medeiros LJ, Miranda RN. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013 Mar; 88(3):219-24. PMID: 23440662.
      View in: PubMed
    251. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013 May; 12(5):577-88. PMID: 23445613.
      View in: PubMed
    252. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs. 2013 Jun; 22(6):687-99. PMID: 23432430.
      View in: PubMed
    253. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9. PMID: 23343175.
      View in: PubMed
    254. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013 Apr 01; 31(10):1285-92. PMID: 23423753.
      View in: PubMed
    255. Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013 Apr 15; 19(8):1933-40. PMID: 23406773.
      View in: PubMed
    256. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5. PMID: 23391517.
      View in: PubMed
    257. Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2. PMID: 23391717.
      View in: PubMed
    258. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol. 2013 Feb; 90(2):89-98. PMID: 23181448.
      View in: PubMed
    259. Quintás-Cardama A, Sever M, Cortes J, Kantarjian H, Verstovsek S. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma. 2013 Sep; 54(9):1959-64. PMID: 23278641.
      View in: PubMed
    260. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28; 121(13):2393-401. PMID: 23325841.
      View in: PubMed
    261. Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med. 2013 Jan; 125(1):128-35. PMID: 23391678.
      View in: PubMed
    262. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013 Jan 15; 19(2):327-35. PMID: 23209034.
      View in: PubMed
    263. Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs. 2012 Dec; 17(4):555-70. PMID: 23186315.
      View in: PubMed
    264. Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol. 2012 Dec; 5(6):631-41. PMID: 23216593.
      View in: PubMed
    265. Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552. PMID: 23121011.
      View in: PubMed
    266. Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012 Nov; 12(9):1098-109. PMID: 22583424.
      View in: PubMed
    267. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91. PMID: 23123105.
      View in: PubMed
    268. Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct; 19(4 Suppl):4-15. PMID: 23042420.
      View in: PubMed
    269. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9. PMID: 23019204.
      View in: PubMed
    270. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):459-62. PMID: 23009979.
      View in: PubMed
    271. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9. PMID: 22820254.
      View in: PubMed
    272. Santos FP, Verstovsek S. Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1083-99. PMID: 23009939.
      View in: PubMed
    273. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012 Aug 01; 5:43. PMID: 22852872.
      View in: PubMed
    274. Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The organic arsenic derivative GMZ27 induces PML-RARa-independent apoptosis in myeloid leukemia cells. Anticancer Res. 2012 Jul; 32(7):2871-80. PMID: 22753750.
      View in: PubMed
    275. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840.
      View in: PubMed
    276. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7. PMID: 22475363.
      View in: PubMed
    277. Santos FP, Verstovsek S. Breakthroughs in myeloproliferative neoplasms. Hematology. 2012 Apr; 17 Suppl 1:S55-8. PMID: 22507780.
      View in: PubMed
    278. Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol. 2012 May; 157(4):426-37. PMID: 22463737.
      View in: PubMed
    279. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 May 10; 119(19):4480-5. PMID: 22431577.
      View in: PubMed
    280. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826.
      View in: PubMed
    281. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41. PMID: 22303899.
      View in: PubMed
    282. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012; 8:95-103. PMID: 22399854.
      View in: PubMed
    283. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 01; 366(9):799-807. PMID: 22375971.
      View in: PubMed
    284. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. RBC-transfusion guidelines update. Leuk Res. 2012 May; 36(5):659-60. PMID: 22336392.
      View in: PubMed
    285. Verstovsek S. Ruxolitinib: the first agent approved for myelofibrosis. Clin Adv Hematol Oncol. 2012 Feb; 10(2):111-3. PMID: 22402352.
      View in: PubMed
    286. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35. PMID: 22271898.
      View in: PubMed
    287. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012; 19(26):4399-413. PMID: 22830345.
      View in: PubMed
    288. Verstovsek S. Therapeutic advances in myeloproliferative neoplasms: the role of new-small molecule inhibitors. Am Soc Clin Oncol Educ Book. 2012; 406-10. PMID: 24451772.
      View in: PubMed
    289. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis. Drugs Today (Barc). 2011 Nov; 47(11):817-27. PMID: 22146225.
      View in: PubMed
    290. Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011 Dec 01; 17(23):7347-58. PMID: 21976548.
      View in: PubMed
    291. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011 Sep; 7(9):1035-43. PMID: 21919691.
      View in: PubMed
    292. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8. PMID: 21846902.
      View in: PubMed
    293. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6. PMID: 21831744.
      View in: PubMed
    294. Quintás-Cardama A, Verstovsek S. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer. 2012 Feb 15; 118(4):870-7. PMID: 21766300.
      View in: PubMed
    295. Quintás-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer. 2011 Dec 15; 117(24):5439-49. PMID: 21692073.
      View in: PubMed
    296. Naqvi K, Verstovsek S, Kantarjian H, Ravandi F. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 2011 Aug; 20(8):1159-66. PMID: 21635221.
      View in: PubMed
    297. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902. PMID: 21622644.
      View in: PubMed
    298. Cortés JE, Freireich EJ, Kantarjian H, Verstovsek S. Retrospect of hematologic malignancies 2010. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S1. PMID: 22035736.
      View in: PubMed
    299. Santos FP, Verstovsek S. JAK2 inhibitors: are they the solution? Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S28-36. PMID: 22035745.
      View in: PubMed
    300. Quintás-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Investig Drugs. 2011 Jul; 20(7):961-72. PMID: 21521147.
      View in: PubMed
    301. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93. PMID: 21523765.
      View in: PubMed
    302. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40. PMID: 21512135.
      View in: PubMed
    303. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877. PMID: 21480207.
      View in: PubMed
    304. Vigil CE, Wang SA, Cortes JE, Bueso-Ramos C, Verstovsek S, Shinder R, Chen SS, Katz RL, Khanna A, Esmaeli B, Manning JT, You MJ, Miranda RN. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6. PMID: 21464405.
      View in: PubMed
    305. Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21. PMID: 21357704.
      View in: PubMed
    306. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011 Feb; 10(2):127-40. PMID: 21283107.
      View in: PubMed
    307. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9. PMID: 21454191.
      View in: PubMed
    308. Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Oncol. 2011 Mar 01; 29(7):781-3. PMID: 21220594.
      View in: PubMed
    309. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20; 29(6):761-70. PMID: 21205761.
      View in: PubMed
    310. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5. PMID: 21127188.
      View in: PubMed
    311. Santos FP, Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev. 2011 Mar; 25(2):53-63. PMID: 21095048.
      View in: PubMed
    312. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519.
      View in: PubMed
    313. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8. PMID: 20952518.
      View in: PubMed
    314. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153. PMID: 20923968.
      View in: PubMed
    315. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76. PMID: 20922795.
      View in: PubMed
    316. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80. PMID: 20886606.
      View in: PubMed
    317. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. PMID: 20843246.
      View in: PubMed
    318. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011 Jan 15; 117(2):327-35. PMID: 20845478.
      View in: PubMed
    319. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. What are RBC-transfusion-dependence and -independence? Leuk Res. 2011 Jan; 35(1):8-11. PMID: 20692036.
      View in: PubMed
    320. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011 Jan; 35(1):12-3. PMID: 20684988.
      View in: PubMed
    321. Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):281-4. PMID: 20709665.
      View in: PubMed
    322. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):285-9. PMID: 20709666.
      View in: PubMed
    323. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9. PMID: 20660823.
      View in: PubMed
    324. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26. PMID: 20372971.
      View in: PubMed
    325. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res. 2010 Apr 01; 16(7):1988-96. PMID: 20215535.
      View in: PubMed
    326. Quintás-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010 Mar; 51(3):540-2. PMID: 20038223.
      View in: PubMed
    327. Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett. 2010 Jul 28; 293(2):167-74. PMID: 20153924.
      View in: PubMed
    328. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15; 115(15):3109-17. PMID: 20130243.
      View in: PubMed
    329. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74. PMID: 20038218.
      View in: PubMed
    330. Feng B, Verstovsek S, Jorgensen JL, Lin P. Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis. Am J Clin Pathol. 2010 Feb; 133(2):314-20. PMID: 20093242.
      View in: PubMed
    331. Millecker L, Lennon PA, Verstovsek S, Barkoh B, Galbincea J, Hu P, Chen SS, Jones D. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer Genet Cytogenet. 2010 Feb; 197(1):1-7. PMID: 20113830.
      View in: PubMed
    332. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9. PMID: 20005966.
      View in: PubMed
    333. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010 Jan 15; 70(2):447-52. PMID: 20068184.
      View in: PubMed
    334. Sever M, Verstovsek S, Erasmus J, Mattiuzzi GN. Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature. Leuk Res. 2010 May; 34(5):e133-6. PMID: 20045559.
      View in: PubMed
    335. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Jan 01; 116(1):93-7. PMID: 19862814.
      View in: PubMed
    336. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51. PMID: 19795507.
      View in: PubMed
    337. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298.
      View in: PubMed
    338. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011 Jan; 19(1):19-26. PMID: 19956980.
      View in: PubMed
    339. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111.
      View in: PubMed
    340. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30. PMID: 19805674.
      View in: PubMed
    341. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20; 27(33):5587-93. PMID: 19786661.
      View in: PubMed
    342. Santos FP, Konoplev SN, Lu H, Verstovsek S. Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia. Leuk Res. 2010 Jan; 34(1):e35-7. PMID: 19748119.
      View in: PubMed
    343. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6. PMID: 19720904.
      View in: PubMed
    344. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525. PMID: 19728024.
      View in: PubMed
    345. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9. PMID: 19652059.
      View in: PubMed
    346. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res. 2009 Jul 15; 15(14):4769-76. PMID: 19584162.
      View in: PubMed
    347. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5. PMID: 19531657.
      View in: PubMed
    348. Nussenzveig RH, Cortes J, Sever M, Quintás-Cardama A, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63. PMID: 19484334.
      View in: PubMed
    349. Sever M, Jorgensen JL, Gurevich I, Pinheiro M, Verstovsek S. Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. Leuk Res. 2009 Nov; 33(11):e186-8. PMID: 19482354.
      View in: PubMed
    350. Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells. Invest New Drugs. 2010 Aug; 28(4):402-12. PMID: 19468689.
      View in: PubMed
    351. Atallah E, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther. 2009 May; 9(5):663-70. PMID: 19445582.
      View in: PubMed
    352. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63. PMID: 19282457.
      View in: PubMed
    353. Jabbour E, Verstovsek S. Treatment of myelofibrosis in younger patients: to transplant or not? Am J Hematol. 2009 Mar; 84(3):131-2. PMID: 19202548.
      View in: PubMed
    354. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203. PMID: 19250674.
      View in: PubMed
    355. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, O'Brien S, Giles F, Albitar M. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Int J Lab Hematol. 2010 Feb; 32(1 Pt 2):95-102. PMID: 19254349.
      View in: PubMed
    356. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009 Jun; 20(6):1080-5. PMID: 19237479.
      View in: PubMed
    357. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4. PMID: 19193436.
      View in: PubMed
    358. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30; 113(18):4171-8. PMID: 19131547.
      View in: PubMed
    359. Apostolidou E, Kantarjian HM, Verstovsek S. JAK2 inhibitors: A reality? A hope? Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S340-5. PMID: 19778862.
      View in: PubMed
    360. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73. PMID: 19118067.
      View in: PubMed
    361. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009; 636-42. PMID: 20008249.
      View in: PubMed
    362. Antic D, Verstovsek S, Elezovic I, Grujicic D, Gotic M, Bila J, Perunicic M, Jakovic L. Spinal epidural granulocytic sarcoma in non-leukemic patient. Int J Hematol. 2009 Jan; 89(1):95-97. PMID: 19109732.
      View in: PubMed
    363. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10. PMID: 19075265.
      View in: PubMed
    364. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, Albitar M. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009 Jan; 11(1):49-53. PMID: 19074595.
      View in: PubMed
    365. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60. PMID: 19060245.
      View in: PubMed
    366. Quintás-Cardama A, Verstovsek S, Freireich E, Kantarjian H, Chen YW, Zingaro R. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem. 2008 Dec; 8(8):904-9. PMID: 19075572.
      View in: PubMed
    367. Verstovsek S. JAK2 inhibitors and myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2008 Dec; 6(12):878-80, 896. PMID: 19209137.
      View in: PubMed
    368. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9. PMID: 19013640.
      View in: PubMed
    369. Verstovsek S. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. Leuk Res. 2009 May; 33(5):617-23. PMID: 19013641.
      View in: PubMed
    370. Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89. PMID: 19002192.
      View in: PubMed
    371. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533.
      View in: PubMed
    372. Johnson MR, Verstovsek S, Jorgensen JL, Manshouri T, Luthra R, Jones DM, Bueso-Ramos CE, Medeiros LJ, Huh YO. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009 Jan; 22(1):50-7. PMID: 19116630.
      View in: PubMed
    373. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7. PMID: 18703706.
      View in: PubMed
    374. Ault P, Cortes J, Lynn A, Keating M, Verstovsek S. Pregnancy in a patient with hypereosinophilic syndrome. Leuk Res. 2009 Jan; 33(1):186-7. PMID: 18597844.
      View in: PubMed
    375. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37. PMID: 18566326.
      View in: PubMed
    376. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45. PMID: 18565853.
      View in: PubMed
    377. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15. PMID: 18559612.
      View in: PubMed
    378. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. PMID: 18482053.
      View in: PubMed
    379. Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009 Jan; 23(1):180-2. PMID: 18509350.
      View in: PubMed
    380. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8. PMID: 18425419.
      View in: PubMed
    381. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70. PMID: 18385750.
      View in: PubMed
    382. Quintás-Cardama A, Harb AJ, Amin HM, Verstovsek S. Granulocytic sarcoma with massive scalp involvement. Am J Hematol. 2008 Apr; 83(4):340-2. PMID: 17685484.
      View in: PubMed
    383. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia. 2008 Sep; 22(9):1790-2. PMID: 18354492.
      View in: PubMed
    384. Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia. 2008 Aug; 22(8):1636-8. PMID: 18305559.
      View in: PubMed
    385. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45. PMID: 18085610.
      View in: PubMed
    386. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96. PMID: 18245540.
      View in: PubMed
    387. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14. PMID: 18223226.
      View in: PubMed
    388. Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008 Jan; 93(1):6-9. PMID: 18166778.
      View in: PubMed
    389. Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008 Jun; 22(6):1295-8. PMID: 18059483.
      View in: PubMed
    390. Quintás-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol. 2007 Dec; 82(12):1124. PMID: 17665501.
      View in: PubMed
    391. Pardanani A, Verstovsek S. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. Cancer J. 2007 Nov-Dec; 13(6):384-91. PMID: 18032976.
      View in: PubMed
    392. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8. PMID: 17849460.
      View in: PubMed
    393. El Rassi FA, Tam CS, Carwile J, Verstovsek S. Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. Leuk Res. 2008 May; 32(5):821-2. PMID: 17870158.
      View in: PubMed
    394. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. PMID: 17623836.
      View in: PubMed
    395. Quintás-Cardama A, Verstovsek S. Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera. Am J Hematol. 2007 Sep; 82(9):859. PMID: 17597478.
      View in: PubMed
    396. Kalac M, Quintás-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer. 2007 Sep 01; 110(5):955-64. PMID: 17654661.
      View in: PubMed
    397. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008 Feb; 22(2):437-8. PMID: 17728787.
      View in: PubMed
    398. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5. PMID: 17625066.
      View in: PubMed
    399. Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun; 35(6):931-8. PMID: 17533047.
      View in: PubMed
    400. Pan J, Quintás-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci. 2007 Aug; 98(8):1223-5. PMID: 17517053.
      View in: PubMed
    401. Pan J, Quintás-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404. PMID: 17495975.
      View in: PubMed
    402. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15; 110(4):1092-7. PMID: 17488875.
      View in: PubMed
    403. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60. PMID: 17342766.
      View in: PubMed
    404. Zhao W, Bueso-Ramos CE, Verstovsek S, Barkoh BA, Khitamy AA, Jones D. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia. 2007 Jul; 21(7):1574-6. PMID: 17410189.
      View in: PubMed
    405. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 01; 109(7):2999-3006. PMID: 17158228.
      View in: PubMed
    406. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Hodge I, Verstovsek S, Segura FJ, Wang H, Prchal J, Yang XF. A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera. Int J Immunopathol Pharmacol. 2007 Apr-Jun; 20(2):373-80. PMID: 17624250.
      View in: PubMed
    407. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007 Nov; 31(11):1503-9. PMID: 17397921.
      View in: PubMed
    408. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906. PMID: 17236224.
      View in: PubMed
    409. Quintás-Cardama A, Verstovsek S. Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase? Leuk Lymphoma. 2007 Mar; 48(3):445-6. PMID: 17454579.
      View in: PubMed
    410. Mesa RA, Quintás-Cardama A, Verstovsek S. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep. 2007 Feb; 2(1):25-33. PMID: 20425385.
      View in: PubMed
    411. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7. PMID: 17223919.
      View in: PubMed
    412. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55. PMID: 17154172.
      View in: PubMed
    413. Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar; 21(3):480-8. PMID: 17215857.
      View in: PubMed
    414. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31(6):737-40. PMID: 17210175.
      View in: PubMed
    415. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, Prchal JT. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007 Jan; 35(1):32-8. PMID: 17198871.
      View in: PubMed
    416. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 01; 109(1):68-76. PMID: 17123268.
      View in: PubMed
    417. Verstovsek S, Quintás-Cardama A, Kantarjian H, Tefferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006 Dec; 15(12):1555-63. PMID: 17107281.
      View in: PubMed
    418. Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol. 2006 Dec; 24(4):181-8. PMID: 16783836.
      View in: PubMed
    419. Xiong Z, Yan Y, Liu E, Silver RT, Verstovsek S, Yang F, Wang H, Prchal J, Yang XF. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol. 2007 Mar; 122(3):279-87. PMID: 17113348.
      View in: PubMed
    420. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res. 2007 May; 31(5):691-4. PMID: 17095087.
      View in: PubMed
    421. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006 Oct 01; 107(7):1429-39. PMID: 16948123.
      View in: PubMed
    422. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S, Wang H, Prchal J, Yang XF. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006 Oct 01; 177(7):4907-16. PMID: 16982933.
      View in: PubMed
    423. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9. PMID: 16955510.
      View in: PubMed
    424. Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Laï JL, Cossement C, Lionne-Huyghe P, Rose C, Bauters F, Preudhomme C. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia. 2006 Nov; 20(11):2067-70. PMID: 16990759.
      View in: PubMed
    425. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer. 2006 Sep 01; 107(5):925-34. PMID: 16832815.
      View in: PubMed
    426. Arana-Yi C, Quintás-Cardama A, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist. 2006 Sep; 11(8):929-43. PMID: 16951397.
      View in: PubMed
    427. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73. PMID: 16951235.
      View in: PubMed
    428. Verstovsek S, Silver RT, Cross NC, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia. 2006 Nov; 20(11):2067. PMID: 16990780.
      View in: PubMed
    429. Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 01; 109(1):315-22. PMID: 16912224.
      View in: PubMed
    430. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711.
      View in: PubMed
    431. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006 Aug; 91(8):1147-8. PMID: 16870548.
      View in: PubMed
    432. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73. PMID: 16855631.
      View in: PubMed
    433. Orsolic N, Golemovic M, Quintás-Cardama A, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci. 2006 Sep; 97(9):952-60. PMID: 16822295.
      View in: PubMed
    434. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60. PMID: 16803568.
      View in: PubMed
    435. Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov; 30(11):1365-70. PMID: 16797704.
      View in: PubMed
    436. Quintás-Cardama A, Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia. 2006 Sep; 20(9):1638-40. PMID: 16791272.
      View in: PubMed
    437. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006 Aug; 134(3):341-3. PMID: 16787500.
      View in: PubMed
    438. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51. PMID: 16688777.
      View in: PubMed
    439. Quintás-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost. 2006 Jun; 32(4 Pt 2):409-16. PMID: 16810616.
      View in: PubMed
    440. Verstovsek S, Giles FJ, Quintás-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec; 30(12):1499-505. PMID: 16682077.
      View in: PubMed
    441. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503. PMID: 16675707.
      View in: PubMed
    442. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. PMID: 16583431.
      View in: PubMed
    443. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64. PMID: 16609064.
      View in: PubMed
    444. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80. PMID: 16502413.
      View in: PubMed
    445. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 01; 24(10):1582-9. PMID: 16575009.
      View in: PubMed
    446. Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res. 2006 Dec; 30(12):1591-5. PMID: 16574225.
      View in: PubMed
    447. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45. PMID: 16545870.
      View in: PubMed
    448. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15. PMID: 16463391.
      View in: PubMed
    449. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. PMID: 16497968.
      View in: PubMed
    450. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22. PMID: 16478631.
      View in: PubMed
    451. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51. PMID: 16403905.
      View in: PubMed
    452. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006 Jan; 50(1):143-7. PMID: 16377679.
      View in: PubMed
    453. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 01; 107(9):3469-73. PMID: 16373661.
      View in: PubMed
    454. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. PMID: 16332390.
      View in: PubMed
    455. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594.
      View in: PubMed
    456. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9. PMID: 16354329.
      View in: PubMed
    457. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24. PMID: 16278404.
      View in: PubMed
    458. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2. PMID: 16195326.
      View in: PubMed
    459. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6. PMID: 16078266.
      View in: PubMed
    460. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      View in: PubMed
    461. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4. PMID: 16123215.
      View in: PubMed
    462. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54. PMID: 15973664.
      View in: PubMed
    463. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      View in: PubMed
    464. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005 Nov 15; 106(10):3370-3. PMID: 16037387.
      View in: PubMed
    465. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7. PMID: 16000593.
      View in: PubMed
    466. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7. PMID: 15861412.
      View in: PubMed
    467. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108. PMID: 15830345.
      View in: PubMed
    468. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56. PMID: 15883410.
      View in: PubMed
    469. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32. PMID: 15867244.
      View in: PubMed
    470. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      View in: PubMed
    471. Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer. 2005 Jan 01; 103(1):32-43. PMID: 15565565.
      View in: PubMed
    472. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6. PMID: 15572595.
      View in: PubMed
    473. Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004 Nov; 77(3):209-14. PMID: 15495258.
      View in: PubMed
    474. Verstovsek S, Estrov Z. Arsenic derivatives as therapeutic agents for hematologic malignancies. Leuk Res. 2004 Sep; 28(9):901-3. PMID: 15234564.
      View in: PubMed
    475. Verstovsek S, Giles FJ, O'Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004 Jul; 28(7):707-11. PMID: 15158092.
      View in: PubMed
    476. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88. PMID: 15198956.
      View in: PubMed
    477. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15; 104(6):1624-30. PMID: 15178574.
      View in: PubMed
    478. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17. PMID: 15131024.
      View in: PubMed
    479. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer. 2004 Apr 15; 100(8):1578-89. PMID: 15073843.
      View in: PubMed
    480. Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer. 2004 Apr 01; 100(7):1459-71. PMID: 15042680.
      View in: PubMed
    481. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58. PMID: 15042679.
      View in: PubMed
    482. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95. PMID: 15059141.
      View in: PubMed
    483. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H, Verstovsek S. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol. 2004 Mar; 124(6):727-38. PMID: 15009060.
      View in: PubMed
    484. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004 Feb 15; 100(4):657-66. PMID: 14770419.
      View in: PubMed
    485. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75. PMID: 14734453.
      View in: PubMed
    486. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004 Apr 15; 103(8):2873-8. PMID: 15070658.
      View in: PubMed
    487. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42. PMID: 14669283.
      View in: PubMed
    488. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. PMID: 12921945.
      View in: PubMed
    489. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. PMID: 12921943.
      View in: PubMed
    490. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407. PMID: 14551133.
      View in: PubMed
    491. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7. PMID: 14508830.
      View in: PubMed
    492. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7. PMID: 12860008.
      View in: PubMed
    493. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52. PMID: 13680159.
      View in: PubMed
    494. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug; 88(8):853-63. PMID: 12935973.
      View in: PubMed
    495. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003 Nov 15; 102(10):3514-20. PMID: 12893761.
      View in: PubMed
    496. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9. PMID: 12842982.
      View in: PubMed
    497. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 2003 Jul; 27(7):661-9. PMID: 12681367.
      View in: PubMed
    498. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer. 2003 Jun 15; 97(12):3010-6. PMID: 12784336.
      View in: PubMed
    499. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86. PMID: 12791647.
      View in: PubMed
    500. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res. 2003 Jun; 27(6):475-9. PMID: 12648505.
      View in: PubMed
    501. Orsolic N, Sver L, Verstovsek S, Terzic S, Basic I. Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom. Toxicon. 2003 Jun; 41(7):861-70. PMID: 12782086.
      View in: PubMed
    502. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3. PMID: 12764375.
      View in: PubMed
    503. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. PMID: 12783207.
      View in: PubMed
    504. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8. PMID: 12712475.
      View in: PubMed
    505. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. PMID: 12752098.
      View in: PubMed
    506. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer. 2003 May 01; 97(9):2212-7. PMID: 12712473.
      View in: PubMed
    507. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7. PMID: 12721247.
      View in: PubMed
    508. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. PMID: 12655528.
      View in: PubMed
    509. Duzkale H, Jilani I, Orsolic N, Zingaro RA, Golemovic M, Giles FJ, Kantarjian H, Albitar M, Freireich EJ, Verstovsek S. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol. 2003 May; 51(5):427-32. PMID: 12736761.
      View in: PubMed
    510. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. PMID: 12649163.
      View in: PubMed
    511. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7. PMID: 12627513.
      View in: PubMed
    512. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003 Jul 01; 102(1):83-6. PMID: 12637317.
      View in: PubMed
    513. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer. 2003 Mar 01; 97(5):1248-52. PMID: 12599232.
      View in: PubMed
    514. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003 Mar; 9(3):976-80. PMID: 12631595.
      View in: PubMed
    515. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15; 97(4):1033-41. PMID: 12569603.
      View in: PubMed
    516. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5. PMID: 12522009.
      View in: PubMed
    517. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6. PMID: 12497210.
      View in: PubMed
    518. Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 2002 Nov 01; 62(21):5995-8. PMID: 12414617.
      View in: PubMed
    519. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ, Albitar M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002 Nov 01; 95(9):1923-30. PMID: 12404286.
      View in: PubMed
    520. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002 Jul; 118(1):151-6. PMID: 12100142.
      View in: PubMed
    521. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002 May 15; 94(10):2653-62. PMID: 12173333.
      View in: PubMed
    522. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002 May 01; 94(9):2416-25. PMID: 12015767.
      View in: PubMed
    523. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002 Mar 15; 99(6):2265-7. PMID: 11877311.
      View in: PubMed
    524. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer. 2002 Mar 01; 94(5):1517-21. PMID: 11920509.
      View in: PubMed
    525. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res. 2001 Dec; 7(12):3884-93. PMID: 11751479.
      View in: PubMed
    526. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 Aug; 15(8):1165-70. PMID: 11480557.
      View in: PubMed
    527. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol. 2001 Aug; 114(2):290-5. PMID: 11529846.
      View in: PubMed
    528. Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2001 Jul; 42(3):511-6. PMID: 11699417.
      View in: PubMed
    529. Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques. 2001 May; 30(5):930-4. PMID: 11355351.
      View in: PubMed
    530. Ehrke MJ, Verstovsek S, Maccubbin DL, Ujházy P, Zaleskis G, Berleth E, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer. 2000 Jul 01; 87(1):101-9. PMID: 10861459.
      View in: PubMed
    531. Verstovsek S, Cabanillas F, Dang NH. CD26 in T-cell lymphomas: a potential clinical role? Oncology (Williston Park). 2000 Jun; 14(6 Suppl 2):17-23. PMID: 10887640.
      View in: PubMed
    532. Verstovsek S, Verschraegen CF, Edwards CL, Malpica A, Kavanagh JJ, Ross MI, Strom EA, Jhingran A, Theriault RL, Kudelka AP. Synchronous primary cancers of the breast and cervix: planning multidisciplinary primary treatment [clinico-pathological conference]. Am J Clin Oncol. 2000 Feb; 23(1):99-103. PMID: 10683089.
      View in: PubMed
    533. Zavadova E, Loercher A, Verstovsek S, Verschraegen CF, Micksche M, Freedman RS. The role of macrophages in antitumor defense of patients with ovarian cancer. Hematol Oncol Clin North Am. 1999 Feb; 13(1):135-44, ix. PMID: 10080073.
      View in: PubMed
    534. Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Meer JM, Mihich E. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer. 1998 May 18; 76(4):579-86. PMID: 9590137.
      View in: PubMed
    535. Ehrke MJ, Verstovsek S, Ujházy P, Meer JM, Eppolito C, Maccubbin DL, Mihich E. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother. 1998 Feb; 45(6):287-98. PMID: 9490198.
      View in: PubMed
    536. Ehrke MJ, Verstovsek S, Zaleskis G, Ho RL, Ujházy P, Maccubbin DL, Mihich E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother. 1996 May; 42(4):221-30. PMID: 8665569.
      View in: PubMed
    537. Ehrke MJ, Verstovsek S, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Mihich E. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer. 1995 Nov 03; 63(3):463-71. PMID: 7591249.
      View in: PubMed
    538. Verstovsek S, Eppolito C, Ujhazy P, Maccubbin DL, Ehrke MJ, Mihich E. Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol. 1995 Jun; 23(6):519-28. PMID: 7768308.
      View in: PubMed
    539. Krawczyk CM, Verstovsek S, Ujházy P, Maccubbin D, Ehrke MJ. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother. 1995 Jun; 40(6):347-57. PMID: 7627991.
      View in: PubMed
    540. Zaleskis G, Verstovsek S, Tzai TS, Mihich E, Ehrke MJ. Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res. 1995; 7(6):307-15. PMID: 8527865.
      View in: PubMed
    541. Verstovsek S, Zaleskis G, Maccubbin DL, Mihich E, Ehrke MJ. Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol. 1994 Dec; 56(6):714-22. PMID: 7996047.
      View in: PubMed
    542. Zaleskis G, Berleth E, Verstovsek S, Ehrke MJ, Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol. 1994 Nov; 46(5):901-8. PMID: 7969078.
      View in: PubMed
    543. Verstovsek S, Maccubbin DL, Ehrke MJ, Mihich E. Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol. 1993; 100(1):47-52. PMID: 8428163.
      View in: PubMed
    544. Verstovsek S, Maccubbin D, Ehrke MJ, Mihich E. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res. 1992 Jul 15; 52(14):3880-5. PMID: 1617664.
      View in: PubMed
    545. Strain differences in induction of murine splenic tumoricidal macrophages by lipopolysaccharide and interleukin 2. Libri Oncologici. 23:157-167.
    546. Prognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia. 16:S105-S113.
    547. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research. 48:1-5.
    548. At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells. Journal of Immunology. 196:4400-4409.
    549. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.
    550. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis. The Lancet.
    551. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma. 1-6.
    552. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.
    553. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera. British Journal of Haematology. 176:76-85.
    554. The author replies. New England Journal of Medicine. 363:2464-2465.
    555. Ruxolitinib versus best available therapy in patients with polycythemia vera. Haematologica. 101:821-829.
    556. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    557. New Therapeutic Approaches in Polycythemia Vera. Clinical Lymphoma, Myeloma and Leukemia. 15:S27-S33.
    558. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.
    559. Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clinical Lymphoma, Myeloma and Leukemia. 15:433-438.
    560. Drug development pipeline for myeloproliferative neoplasms. JNCCN Journal of the National Comprehensive Cancer Network. 14:1613-1624.
    561. Novel insights into myelofibrosis pathophysiology and treatment.
    562. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma. 1-5.
    563. Eosinophilia in Hematologic Disorders. Immunology and Allergy Clinics of North America. 35:439-452.
    564. Plasma hepatocyte growth factor is prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Blood. 96.
    565. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American Journal of Clinical Pathology. 145:418-427.
    566. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. 56:2092-2097.
    567. Highlights in polycythemia vera from the 2016 EHA congress. Clinical Advances in Hematology and Oncology. 14:810-813.
    568. A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia. Journal of Pediatric Hematology/Oncology.
    569. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer.
    570. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology, Immunotherapy. 45:60.
    571. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. Journal of Experimental Medicine. 213:1723-1740.
    572. A comprehensive review of pacritinib in myelofibrosis. Future Oncology. 11:2819-2830.
    573. Polycythemia Vera. 152-155.
    574. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome - Negative myeloproliferative neoplasms. Clinical Lymphoma, Myeloma and Leukemia. 15:253-261.
    575. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed. Leukemia and Lymphoma.
    576. Ruxolitinib dose management as a key to long-term treatment success. International Journal of Hematology. 1-10.
    577. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis. Haematologica. 100:479-488.
    578. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease. American Journal of Hematology.
    579. Systemic mastocytosis. Drugs of the Future. 33:187-192.
    580. Novel therapies for myelofibrosis. Leukemia and Lymphoma. 56:2768-2778.
    581. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    582. Advanced systemic mastocytosis. Haematologica. 101:1133-1143.
    583. Myelofibrosis-associated complications. International Journal of General Medicine. 7:89-101.
    584. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 128:877-880.
    585. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy. 7:13-21.
    586. Extramedullary acute myeloid leukemia. Frontiers in Oncology. 4 JUN.
    587. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102:79-84.
    588. Foreword. Unknown Journal. 2-5.
    589. Dr. Verstovsek and Colleagues reply. New England Journal of Medicine. 366:2034.
    590. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology.
    591. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100:1139-1145.
    592. Bone marrow fibrosis in myelofibrosis. Haematologica. 101:660-671.
    593. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia.
    594. Long non-coding RNAs in primary myelofibrosis. Leukemia and Lymphoma. 56:281-282.
    595. Overcoming treatment challenges in myelofibrosis and polycythemia vera. Cancer Chemotherapy and Pharmacology. 1-18.
    596. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology. 8:391-401.
    597. JAK inhibitors as therapy for myelofibrosis. 104-122.
    598. Ruxolitinib and DNA methyltransferase-inhibitors. Leukemia and Lymphoma. 56:279-280.
    599. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology.
    600. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. 362-372.
    601. Myeloproliferative neoplasms, version 2.2017. JNCCN Journal of the National Comprehensive Cancer Network. 14:1572-1611.
    602. Current Opinion in Hematology.
    603. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. JNCCN Journal of the National Comprehensive Cancer Network. 13:424-434.
    604. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    605. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    606. Erratum. Nature Reviews Drug Discovery. 10:318.
    607. Primary myelofibrosis associated glomerulopathy. BMC Nephrology. 16.
    608. Pharmacotherapy of polycythemia vera. Expert Opinion on Orphan Drugs. 1:977-985.
    609. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    610. Ruxolitinib for myelofibrosis. ONCOLOGY (United States). 27.
    611. Pacritinib. Drugs of the Future. 38:375-386.
    612. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opinion on Investigational Drugs. 25:1393-1403.
    613. New therapies for polycythemia vera. Clinical Advances in Hematology and Oncology. 13:356-358.
    614. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 101:e482-e484.
    615. Myelofibrosis. Expert Opinion on Pharmacotherapy. 17:2375-2389.
    616. Second line therapies in polycythemia vera. Critical Reviews in Oncology/Hematology.
    617. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation. 22:1348-1356.
    618. Mechanisms of thrombogenesis in polycythemia vera. Blood Reviews. 29:215-221.
    619. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 102:94-102.
    620. Significance of angiogenin plasma concentrations in patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 96.
    621. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia.
    622. Use of the functional assessment of cancer therapy-anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clinical Therapeutics. 36:560-566.
    623. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor. Journal of Experimental Pharmacology. 8:11-19.
    624. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leukemia Research. 38:91-94.
    625. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. Journal of Hematology and Oncology. 9.
    626. Cyclosporine A differetly affects the function of the two main T cell subsets. Croatian Medical Journal. 33:102-106.
    627. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms. Cancer.
    628. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. American Journal of Hematology. 90:1091-1092.
    629. Myelofibrosis. 1734-1745.
    630. Clinical relevance of vascular endothelial growth factor (vegf) receptors 1 and 2 in acute myelobd leukemia (aml) and myelodysplastic syndromes (mds). Blood. 96.
    631. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia.
    632. Primary autoimmune myelofibrosis. International Journal of Hematology. 1-4.
    633. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 122:681-692.
    634. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.
    VERSTOVSEK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (919) concept(s)
    _
    Co-Authors Expand Description
    See all (138) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department